drugset / Trial / NCT01000402
Juvenile Bipolar Disorder Outpatient Program
Phase 4
Unknown
150 enrolled
Federal University of Rio Grande do Sul
Hospital de Clinicas de Porto Alegre · collab
NaSingle-groupOpen-label
Summary
This is an outpatient program for children and adolescents with bipolar disorders. The naturalistic approach of the program will allow a proper investigation of the disorder, assessment of environmental and biological factors, the conduction of treatment studies, and follow-up of the subjects.
Timeline
- Start
- 2008-02
- Primary completion
- 2012-10
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 20 mg | — |
| Subject | Fluoxetine | Small molecule | 1 mg | — |
| Subject | Fluoxetine | Small molecule | 40 mg | — |
| Subject | Lamotrigine | Small molecule | 25 mg | — |
| Subject | Lamotrigine | Small molecule | 200 mg | — |
| Subject | Lithium | Unknown | 150 mg | — |
| Subject | Lithium | Unknown | 1500 mg | — |
| Subject | Methylphenidate | Small molecule | 0.3 mg/kg | — |
| Subject | Methylphenidate | Small molecule | 0.7 mg/kg | — |
| Subject | Olanzapine | Small molecule | 2.5 mg | — |
| Subject | Olanzapine | Small molecule | 20 mg | — |
| Subject | Quetiapine | Small molecule | 25 mg | — |
| Subject | Quetiapine | Small molecule | 500 mg | — |
| Subject | Risperidone | Other / unclassified | 0.5 mg | — |
| Subject | Risperidone | Other / unclassified | 6 mg | — |
| Subject | Sertraline | Small molecule | 25 mg | — |
| Subject | Sertraline | Small molecule | 200 mg | — |
| Subject | Topiramate | Small molecule | 25 mg | — |
| Subject | Topiramate | Small molecule | 300 mg | — |
| Subject | Valproate | Small molecule | 125 mg | — |
| Subject | Valproate | Small molecule | 2000 mg | — |
| Subject | Ziprasidone | Small molecule | 40 mg | — |
| Subject | Ziprasidone | Small molecule | 160 mg | — |